X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) has announced it will report its third-quarter 2024 financial results and present findings from its completed Phase 2 clinical trial of mavorixafor in chronic neutropenia patients on November 13, 2024. The company will host a conference call and webcast at 8:00 a.m. ET on the same day. The presentation will be accessible via phone and through the company's investor relations website, with a replay available afterward.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
On the day this news was published, XFOR declined 3.95%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024.
The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accompanying slide presentation will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the conclusion of the call and webcast, a replay will be available on the company’s website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will X4 Pharmaceuticals (XFOR) report its Q3 2024 financial results?
What clinical trial results will X4 Pharmaceuticals (XFOR) present on November 13, 2024?
How can investors access X4 Pharmaceuticals' (XFOR) Q3 2024 earnings call?
